News
12-10-2010, 04:50 AM
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
More... (http://www.news-medical.net/news/20101210/Everolimus-plus-tamoxifen-delays-disease-progression-in-HR2bHER2-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20101210/Everolimus-plus-tamoxifen-delays-disease-progression-in-HR2bHER2-metastatic-breast-cancer.aspx)